<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel rdf:about="http://hdl.handle.net/10453/35222">
    <title>OPUS Community:</title>
    <link>http://hdl.handle.net/10453/35222</link>
    <description />
    <items>
      <rdf:Seq>
        <rdf:li rdf:resource="http://hdl.handle.net/10453/194853" />
        <rdf:li rdf:resource="http://hdl.handle.net/10453/194852" />
        <rdf:li rdf:resource="http://hdl.handle.net/10453/188088" />
        <rdf:li rdf:resource="http://hdl.handle.net/10453/187901" />
      </rdf:Seq>
    </items>
    <dc:date>2026-06-10T05:54:23Z</dc:date>
  </channel>
  <item rdf:about="http://hdl.handle.net/10453/194853">
    <title>How simple can a treatment for early stuttering be? A proposed two-factor early intervention</title>
    <link>http://hdl.handle.net/10453/194853</link>
    <description>Title: How simple can a treatment for early stuttering be? A proposed two-factor early intervention
Authors: Onslow, M; Hearne, A; Yu, K; O'Brian, S; Menzies, R; Lowe, R
Abstract: In this clinical focus article, we draw attention to the need for immediate intervention shortly after stuttering onset. More than half of stuttering onsets occur before 3 years of age. We argue that existing interventions for preschool children who stutter require varying levels of cognitive engagement from children; hence, they are not suitable for children of that age. For this reason, we argue that there is no clinical trials evidence for treatment efficacy with children younger than 3 years of age. There are many recommended parent strategies that do not require any active participation from children, which, therefore, may be suitable for immediate stuttering intervention. Two of these have laboratory support in their favor: parent speech rate reduction and increased interturn speaker latency. Therefore, we developed a clinical protocol based on those two parent strategies and showed the clinical viability of the protocol with three children who stuttered. We argue that automation of our proposed treatment with lifelike artificial intelligence–generated avatar clinicians will make it globally viable, and a suitable target for future Phases I–IV clinical trials.</description>
    <dc:date>2026-03-10T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/10453/194852">
    <title>A Phase I trial of iLidcombe: Online treatment for young children who stutter</title>
    <link>http://hdl.handle.net/10453/194852</link>
    <description>Title: A Phase I trial of iLidcombe: Online treatment for young children who stutter
Authors: Ross, F; Onslow, M; Jones, M; Menzies, R; Packman, A; O'Brian, S; Hearne, A; Lowe, R
Abstract: AIM: The aim of this Phase I trial was to assess the safety, compliance, and potential efficacy of iLidcombe, a standalone internet version of the Lidcombe Program for young children who stutter. METHOD: We used a prospective single-group design involving 6 months of access to iLidcombe. Assessments occurred pretreatment and after 6 months of access. Participants were 20 parents of young children who stuttered. RESULTS: There was evidence of stuttering severity reduction after using iLidcombe for 6 months. Compliance with the program was favorable, and there was no suggestion of any psychologically adverse impact on children. CONCLUSION: The results of this Phase I trial provide a roadmap for further Phases II-IV clinical trial development.</description>
    <dc:date>2026-04-27T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/10453/188088">
    <title>Sexuality and Intimacy</title>
    <link>http://hdl.handle.net/10453/188088</link>
    <description>Title: Sexuality and Intimacy
Authors: Power, E; McGrath, M; Lever, S</description>
    <dc:date>2024-01-01T00:00:00Z</dc:date>
  </item>
  <item rdf:about="http://hdl.handle.net/10453/187901">
    <title>"How well do we know our patients?": Further validation of a complexity rating scale for HIV.</title>
    <link>http://hdl.handle.net/10453/187901</link>
    <description>Title: "How well do we know our patients?": Further validation of a complexity rating scale for HIV.
Authors: Begley, K; Smith, D; Wand, H; Chan, D; Furner, V; Kelly, ML; McGrath, P; Hennessy, R; Price, A; Purnomo, L; Bowden, BH; Bulsara, SM
Abstract: BACKGROUND: Despite advances in the management and treatment of HIV, identifying risks for disengagement are essential to maximize positive outcomes. The current study investigated the validity of the Clinical Complexity Rating Scale for HIV (CCRS-HIV), a risk-prediction tool, by assessing agreement between patient and clinician scores of patient complexity. METHODS: 207 patients completed the patient version of the CCRS-HIV (CCRS-HIVP), and six Attending Medical Officers (AMOs) caring for those individuals completed the original clinician version (CCRS-HIVC). Kappa statistics, sensitivity and specificity were used to assess patient-clinician agreement. RESULTS: Patient-clinician agreement was highest for problematic crystal methamphetamine use (86%), polypharmacy (84%) and other physical health concerns (67%). Cut-offs of 40 and 45 for the total CCRS-HIV score were identified as most appropriate, with high sensitivity (79.31% and 76.0% respectively). CONCLUSIONS: Overall agreement between the clinician and patient complexity scores was high. These findings provide further evidence of the validity of the scale. The study demonstrates that the unique role of AMOs at the center contributes to them knowing their patients well, allowing them to manage and refer when required for interdisciplinary care which likely contributes to their ongoing engagement in care and may account for the high level of agreement.</description>
    <dc:date>2024-12-01T00:00:00Z</dc:date>
  </item>
</rdf:RDF>

